ABSTRACT
Herein is described the development of a large-scale manufacturing process for molnupiravir, an orally dosed antiviral that was recently demonstrated to be efficacious for the treatment of patients with COVID-19. The yield, robustness, and efficiency of each of the five steps were improved, ultimately culminating in a 1.6-fold improvement in overall yield and a dramatic increase in the overall throughput compared to the baseline process.
All Keywords
【저자키워드】 COVID-19, Antiviral, molnupiravir, crystallization, 【초록키워드】 Treatment, Efficiency, dramatic increase, FIVE, described, demonstrated, baseline, dosed, patients with COVID-19, 【제목키워드】 development, route,
【저자키워드】 COVID-19, Antiviral, molnupiravir, crystallization, 【초록키워드】 Treatment, Efficiency, dramatic increase, FIVE, described, demonstrated, baseline, dosed, patients with COVID-19, 【제목키워드】 development, route,